Aquestive Therapeutics, Inc.

AQSTNASDAQHealthcare● Active

$3.96

+$0.03(+0.64%)

Market Cap$392757745

P/E Ratio—

52W High$7.55

52W Low$2.93

Avg Volume1.6M

Open$4.00

Beta1.45

Cash on Hand Financials Revenue

Aquestive Therapeutics, Inc. (AQST) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

AQST · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$121.2M▲ +69.4% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$121.2M

cashAndCashEquivalents

Short-Term Investments

shortTermInvestments

YoY Change vs Prior Year

+69.4%

vs prior fiscal year

Latest Quarter

$110.7M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$121.2MCash on Hand

Total Debt$131.4MTotal Debt

Net Cash / Net Debt−$10.3MNet Debt Position

Cash vs Debt Ratio

Cash 48%Aquestive Therapeutics, Inc. cash as % of market cap: 30.85%% · MCap $0BDebt 52%

Aquestive Therapeutics, Inc. carries a net debt position of $10.3M. Total debt ($131.4M) exceeds cash on hand ($121.2M). Aquestive Therapeutics, Inc. cash vs debt ratio: 48% cash / 52% debt.

Net Cash = Cash & ST Investments − Total Debt$121.2M − $131.4M = −$10.3M

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

AQST annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

AQST cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$121.2M+69.4%

Dec 31, 2024FY$71.5M+199.7%

Dec 31, 2023FY$23.9M-12.5%

Dec 31, 2022FY$27.3M-2.7%

Dec 31, 2021FY$28.0M-11.9%

AQST cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

AQST vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Aquestive Therapeutics, Inc.YOU

AQST

$121.2M$393M30.9%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Aquestive Therapeutics, Inc. (AQST) cash on hand as of December 31, 2025 is $121.2M, comprising $121.2M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Aquestive Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Aquestive Therapeutics, Inc. cash reserves or cash position.

Aquestive Therapeutics, Inc. annual cash on hand history shows increased +69.4% in 2025: increased +69.4% in 2025. Aquestive Therapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Aquestive Therapeutics, Inc. carries total debt of $131.4M against cash of $121.2M, resulting in a net debt position of -$10.3M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

AQST cash on hand · 5 questions

As of December 31, 2025, Aquestive Therapeutics, Inc. (AQST) has $121,169,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $121,169,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2026): $110,734,000. Data sourced from the annual 10-K filing via FMP.

AQST cash on handAQST cash reservesAQST cash 2025how much cash does AQST have

▸ Source: FMP /balance-sheet-statement · US GAAP · Aquestive Therapeutics, Inc. · Aquestive Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025